Unexpected metabolic effects of sodium-glucose cotransporter 2 inhibitors
The sodium-glucose cotransporter 2 (SGLT2) is exclusively expressed in the brush border of the proximal tubule of the kidney, where it effects glucose reabsorption. However, a recent study of young persons with type 2 diabetes (T2D) and early kidney injury showed that treatment with SGLT2 inhibitors (SGLT2i) was associated with significant transcriptional changes across virtually all tubular segments in the kidney.1 SGLT2i are not only effective in treating diabetic kidney disease but also in protecting against both heart and kidney failure in various types of chronic kidney disease (CKD).
Source: Kidney International - Category: Urology & Nephrology Authors: Tilman B. Drueke, Ziad A. Massy Tags: Nephrology Digest Source Type: research
More News: Cardiology | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Heart | SGLT2 Inhibitors | Sodium | Study | Urology & Nephrology